Together, our findings provide crucial insights into a novel NRP1/PKC axis to reveal promising new therapeutic targets in the treatment of PCa patients with NED and point to NRP1 as an early biomarker in tumour cell transition to the drug-resistant NE phenotype. This evidence concerns the gene PRRT2 and posterior cortical atrophy.